Avalon globocare provides updates on its lead scientific and clinical programs in car t-cell therapy and covid-19

Avalon globocare provides updates on its lead scientific and clinical programs in car t-cell therapy and covid-19.avalon globocare corp - successfully completed pre-clinical research on ava-011, including tumor cytotoxicity studies.avalon globocare corp - achieved 90% cr rate with minimum toxicity/adverse side effects in phase i study of 4-1bb based anti-cd19 car-t therapy.avalon globocare corp - expect to launch first-in-human trial of ava-011 in q1 2021.
AVCO Ratings Summary
AVCO Quant Ranking